- Adagene Presents Clinical Data for Anti-CTLA-4 SAFEbody® ADG126 Reinforcing Best-in-Class Safety Profile at Repeat Doses and Showing Early Efficacy Profile in Advanced/Metastatic Solid Tumors
- Allogene Therapeutics Presents Interim Phase 1 Data on ALLO-316 in Renal Cell Carcinoma
- Amgen To Present Long-Term Outcomes For Lumakras® (Sotorasib) in KRAS G12C-Mutated NSCLC
- AstraZeneca advances its pipeline and highlights progress in immuno-oncology, ADCs, cell therapy and epigenetics
- BeiGene to Present Clinical Results and Biomarker Data on Tislelizumab in Solid Tumors
- Imfinzi-based treatment before & after surgery reduced the risk of disease recurrence, progression events or death by 32% in resectable NSCLC in the AEGEAN Phase III trial
- Innovent Announces Overall Survival Results of Phase 2 Study of Pemazyre® (pemigatinib) in Chinese Patients with Advanced Cholangiocarcinoma
- Innovent Announces Updated Data of Phase 1 Clinical Trial for IBI351 (KRASG12C Inhibitor) as Monotherapy for Solid Tumors
- Innovent Releases Final Analysis Results of ORIENT-16: the Phase 3 Study of Sintilimab in Combination with Chemotherapy for 1L Treatment of Gastric Cancer
- Kintara Therapeutics Announces Data Presentation of new solid tumor cancer therapies
- Lilly Announces Details of Presentations
- Merck’s KEYTRUDA + chemo Significantly Improved OS Compared to Chemotherapy Alone in Patients With Advanced or Unresectable Biliary Tract Cancer
- Merus Announces Publication of an Abstract on Petosemtamab in Advanced Gastric/Esophageal Adenocarcinoma
- Merus’ Petosemtamab Interim Data Demonstrates Clinically Meaningful Activity in Previously Treated Head and Neck Squamous Cell Carcinoma (HNSCC)
- MorphoSys & Incyte Announce Five-Year Results Of L-MIND Study Showed Durable Responses In R/R DLBCL Patients Treated With Monjuvi® (Tafasitamab-Cxix)
- Neoadjuvant Opdivo with Chemotherapy Significantly Improves Event-Free Survival in Patients with Resectable NSCLC in Phase 3 CheckMate -816 Trial
- New Data Showing that Transgene and NEC’s Individualized Cancer Vaccine TG4050 Induces Strong and Specific Immune Responses against Tumors
- Novel Allogeneic CAR T Cell Therapy Delivers Promising Early Results In Patients With Metastatic Clear Cell Renal Cell Carcinoma
- Novartis Announces Early Clinical Data For Unique KRASG12C Inhibitor
- RenovoRx Presenting Phase III Clinical Trial Interim Analysis Data of the TIGeR-PaC Study
- Roche’s Tecentriq plus Avastin reduced the risk of cancer returning in people with certain types of adjuvant liver cancer in a Phase III study
- Seagen to Present New Clinical Data From Broad Portfolio of Targeted Cancer Therapeutics
- Strata Oncology Announces Four Abstracts Accepted for Presentation
- Three Year Follow-Up Data from Phase 3 CROWN Trial of Pfizer’s LORBRENA® (lorlatinib) Confirm Prolonged PFS in 1L ALK-Positive Advanced Lung Cancer
- Transgene and NEC’s Individualized Cancer Vaccine TG4050 Induces Strong and Specific Immune Responses against Tumors